Real-world remdesivir data add to body of evidence for Gilead Sciences Covid-19 drug

In the eight months since the Gilead Sciences antiviral drug remdesivir became the first FDA-approved treatment for Covid-19, the company has been collecting real-world data about drug’s effect. The data continue to show that the drug reduces the risk of death and helps patients get discharged from the hospital sooner.